Adipose-muscle crosstalk during the menopausal transition: mechanistic links to sarcopenic obesity in midlife women.
Zhang W., Wu Q., Chen Q., Qin W., Zhang D., Xu Q.
Narrative Review, published in Front Endocrinol (Lausanne) (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Front Endocrinol (Lausanne) (2026)
- Country
- Switzerland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42158910
- DOI
- 10.3389/fendo.2026.1805067
Abstract (original English)
Midlife represents a biological "phenotype transition" for women, during which sarcopenic obesity risk can rise despite stable BMI. Evidence anchored to the STRAW + 10 framework suggests that the interval surrounding the final menstrual period is an acceleration window for fat gain and centripetal/ectopic redistribution, creating an "invisible remodeling" trajectory that may increase the risk of developing sarcopenic obesity, which is not captured by routine anthropometrics. We synthesize mechanisms linking menopausal biology to increased risk of sarcopenic obesity: obesity-driven inflammation, adipokine dysregulation, and lipotoxic flux that impair insulin-AKT signaling and metabolic flexibility, coupled with reduced contractile/endocrine muscle output that worsens adipose phenotype. A key mediator is myosteatosis, comprising intramyocellular lipid and intermuscular adipose tissue, which can reduce specific force and manifest as dynapenia even when muscle size is preserved. Scalable monitoring of muscle quality using ultrasound echo intensity may complement CT/MRI in midlife practice. Estrogen withdrawal may further amplify energetic and regenerative vulnerability via ERα-related mitochondrial quality control and satellite-cell support, although menopause-stage human longitudinal data remain limited. In the GLP-1 era, lean mass loss during weight reduction and rapid regain aft
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.